When Noah Delano was a toddler, the simplest things — a crayon gripped too tightly, a stumble on the playground — would leave him with painful, thickened skin on his hands and feet. His family spent years navigating misdiagnoses before learning he had pachyonychia congenita (PC), a rare genetic disorder caused by mutations in a keratin gene called KRT16. Today, new research offers a clearer picture of what goes wrong — and points toward a treatment already within reach.
Scientists have long understood keratin as the sturdy structural protein that builds hair, nails, and skin. But a study published in Science Translational Medicine reveals a more surprising role for one of its variants, Keratin 16 (K16): it doesn't just give cells their shape — it acts as a master regulator of inflammation, keeping the skin's immune defenses from spiraling out of control.
The research team, which examined skin biopsies and genetic data from patients with PC and psoriasis, found that K16 physically binds to proteins involved in the type I interferon signaling pathway. In healthy skin, this interaction acts like a brake, preventing the immune system from over-reacting to everyday environmental stress. But when K16 is mutated or clumps together improperly — as it does in PC patients — that brake fails. Interferon signals surge, immune cells rush in, and painful lesions form.
To test this mechanism thoroughly, the researchers took a three-pronged approach: they analyzed human patient samples, bred mice genetically lacking K16, and used CRISPR to knock out the protein in lab-grown human cells. In every case, the results pointed the same direction. Without K16 functioning normally, skin cells mounted an exaggerated immune response, essentially stuck in an alarm state.
The discovery reframes PC as an immune-driven condition rather than simply a structural one. More importantly, it suggests an existing treatment could help. The team applied ruxolitinib (marketed as Opzelura), a medicated cream already approved for other inflammatory skin conditions, to mice with PC-like lesions. By blocking the overactive immune signals — ruxolitinib is a Janus kinase (JAK) inhibitor — the cream reduced lesion thickness by approximately 25 percent within just one week.
For patients like Noah, now in his twenties, the findings offer genuine hope. "Understanding that the problem isn't just about the keratin being thick, but about the immune system being stuck in overdrive — that's a game changer," said his dermatologist, who was not involved in the study. Targeted creams that restore balance to the interferon pathway could eventually replace more invasive treatments.
The researchers are now planning follow-up studies in human patients. If the results hold, ruxolitinib or similar immune-calming creams could become a first-line therapy for PC — transforming management of a painful, lifelong condition into something far simpler: a cream applied at home.